Xstrahl Spotlights Full Range of X-Ray Therapy and Radiation Research Systems at DEGRO 2019, June 13-16
13th June, 2019
Xstrahl Spotlights Full Range of X-Ray Therapy and Radiation Research Systems at DEGRO 2019, June 13-16th
Company also announces launch of patient-focused, German-language website providing information on treatment options for a range of benign conditions
Xstrahl, global leader in orthovoltage radiotherapy devices to treat benign dermatological conditions, is showcasing its market-leading range of treatment systems and pre-clinical radiation research platforms at the DEGRO 2019 congress in Munster, Germany.
Among the products spotlighted at Germany’s leading radiation oncology event is the Xstrahl 200 system, which is used routinely at hundreds of hospitals worldwide to treat a non-melanoma skin cancer and a range of benign conditions such as Dupuytren’s Contracture, Peyronie’s Disease and Gynecomastia. In addition, the Xstrahl 200 enables orthovoltage therapy for palliative care, including treatment of soft tissue metastases and secondary lesions.
Xstrahl’s family of treatment planning and information management software products will also be on show, including DICOM and HL7-based connectivity options to third party oncology information databases such as ARIA and Mosaiq.
Also spotlighted at DEGRO is the Small Animal Radiation Research Platform (SARRP), the most advanced commercially available 3D image guided micro irradiator and Xstrahl’s flagship pre-clinical research system. Through state-of-the-art image acquisition, reconstruction, and treatment planning, SARRP serves as a dynamic research tool for preclinical radiobiology research.
To mark the first day of the show, Xstrahl is also announcing the launch of a new, free web-based resource focused on the treatment of benign conditions using orthovoltage radiotherapy. The German-language website (www.xstrahl-roentgentherapie.de) contains a wealth of information for patients and clinicians, and includes comprehensive FAQs about benign conditions and treatment options.